Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ.

J Med Chem. 2018 Nov 21;61(22):9889-9907. doi: 10.1021/acs.jmedchem.8b01187. Epub 2018 Nov 10.


Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.


Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.

Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST.

Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355.


TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.

Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, Yamamoto S, Robinson DT, Li CJ.

Cancer Immunol Immunother. 2015 Oct;64(10):1229-39. doi: 10.1007/s00262-015-1730-4. Epub 2015 Jun 20.


A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ.

Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.


8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.

Carbain B, Paterson DJ, Anscombe E, Campbell AJ, Cano C, Echalier A, Endicott JA, Golding BT, Haggerty K, Hardcastle IR, Jewsbury PJ, Newell DR, Noble ME, Roche C, Wang LZ, Griffin RJ.

J Med Chem. 2014 Jan 9;57(1):56-70. doi: 10.1021/jm401555v. Epub 2013 Dec 23.


Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JW, Odedra R, Page K, Perkins P, Suleman A, Tam K, Thommes P, Broadhurst R, Wood C.

J Med Chem. 2013 Mar 14;56(5):2125-38. doi: 10.1021/jm301859s. Epub 2013 Mar 1.


Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.

Cumming JG, McKenzie CL, Bowden SG, Campbell D, Masters DJ, Breed J, Jewsbury PJ.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94.


Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.

Anderson M, Beattie JF, Breault GA, Breed J, Byth KF, Culshaw JD, Ellston RP, Green S, Minshull CA, Norman RA, Pauptit RA, Stanway J, Thomas AP, Jewsbury PJ.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3021-6.


Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

Breault GA, Ellston RP, Green S, James SR, Jewsbury PJ, Midgley CJ, Pauptit RA, Minshull CA, Tucker JA, Pease JE.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2961-6.


Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.

Beattie JF, Breault GA, Ellston RP, Green S, Jewsbury PJ, Midgley CJ, Naven RT, Minshull CA, Pauptit RA, Tucker JA, Pease JE.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2955-60.


FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function.

Taylor RD, Jewsbury PJ, Essex JW.

J Comput Chem. 2003 Oct;24(13):1637-56.


A review of protein-small molecule docking methods.

Taylor RD, Jewsbury PJ, Essex JW.

J Comput Aided Mol Des. 2002 Mar;16(3):151-66. Review.


Supplemental Content

Loading ...
Support Center